Fong Clinical Risk Score for CRC Liver Metastases
Predicts survival after resection of colorectal cancer liver metastases. Five clinical risk factors predict recurrence and survival after hepatectomy.
Score interpretation
Score 0 — 5-year survival ~60%
→ Excellent candidate for liver resection; proceed with curative intent
Score 1–2 — 5-year survival ~40–47%
→ Good candidate for resection; discuss expected outcomes with patient
Score 3 — 5-year survival ~20%
→ Consider resection with careful patient selection and MDT discussion; neoadjuvant chemotherapy may improve selection
Score 4–5 — 5-year survival <14%
→ High recurrence risk; consider chemotherapy ± targeted therapy first; resection controversial — MDT decision
Interpretation bands for the Fong Score. Apply clinical judgement and local guidance.
References
- Fong Y et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg. 1999;230(3):309–321.
Related
Curated clinical cross-links plus same-class fallbacks.
- FLIPI — Follicular Lymphoma International Prognostic Index · Cancer Prognosis
- CLL-IPI (International Prognostic Index for CLL) · Cancer Prognosis
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- WPSS — WHO Prognostic Scoring System for MDS · Cancer Prognosis
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Denosumab · Anti-RANKL Monoclonal Antibody
- Pamidronate Disodium · IV Bisphosphonate (Paget's Disease / Bone Metastases / Hypercalcaemia)
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.